{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:39:28Z","timestamp":1792715968020,"version":"4.5.0"},"reference-count":427,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"DOI":"10.1038\/s41568-026-00983-3","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:02:17Z","timestamp":1792684937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer theranostics"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7475-2526","authenticated-orcid":false,"given":"Alexandros Marios","family":"Sofias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-4391","authenticated-orcid":false,"given":"Michelle S.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gooitzen M.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7854-4345","authenticated-orcid":false,"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-6805","authenticated-orcid":false,"given":"Twan","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"983_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.123.265670","volume":"64","author":"WA Weber","year":"2023","unstructured":"Weber, W. A. et al. What is theranostics? J. Nucl. Med. 64, 669\u2013670 (2023).","journal-title":"J. Nucl. Med."},{"key":"983_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 597\u2013610 (2023).","journal-title":"Lancet Oncol."},{"key":"983_CR3","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg, J. R. et al. 177Lu-DOTATATE plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 1752\u20131763 (2021).","journal-title":"Lancet Oncol."},{"key":"983_CR4","first-page":"255","volume":"73","author":"EO Aboagye","year":"2023","unstructured":"Aboagye, E. O., Barwick, T. D. & Haberkorn, U. Radiotheranostics in oncology: making precision medicine possible. CA: Cancer J. Clin. 73, 255\u2013274 (2023).","journal-title":"CA: Cancer J. Clin."},{"key":"983_CR5","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh, S. et al. 177LuLu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403, 2807\u20132817 (2024).","journal-title":"Lancet"},{"key":"983_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET\u2013CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208\u20131216 (2020).","journal-title":"Lancet"},{"key":"983_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"983_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017).","journal-title":"N. Engl. J. Med."},{"key":"983_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.ijrobp.2025.04.019","volume":"122","author":"PJ Keall","year":"2025","unstructured":"Keall, P. J. et al. Real-time dose-guided radiation therapy. Int. J. Radiat. Oncol. 122, 787\u2013801 (2025).","journal-title":"Int. J. Radiat. Oncol."},{"key":"983_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62389-1","volume":"14","author":"S Bennett","year":"2024","unstructured":"Bennett, S. et al. Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging. Sci. Rep. 14, 11959 (2024).","journal-title":"Sci. Rep."},{"key":"983_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamasurg.2020.1314","volume":"155","author":"HK Kim","year":"2020","unstructured":"Kim, H. K. et al. Evaluation of intraoperative near-infrared fluorescence visualization of the lung tumor margin with indocyanine green inhalation. JAMA Surg. 155, 732\u2013740 (2020).","journal-title":"JAMA Surg."},{"key":"983_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","volume":"103","author":"K Maier-Hauff","year":"2011","unstructured":"Maier-Hauff, K. et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103, 317\u2013324 (2011).","journal-title":"J. Neurooncol."},{"key":"983_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(12)70334-0","volume":"13","author":"MLJ Smits","year":"2012","unstructured":"Smits, M. L. J. et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 13, 1025\u20131034 (2012).","journal-title":"Lancet Oncol."},{"key":"983_CR14","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/S1470-2045(19)30317-1","volume":"20","author":"S Hernot","year":"2019","unstructured":"Hernot, S., van Manen, L., Debie, P., Mieog, J. S. D. & Vahrmeijer, A. L. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol. 20, e354\u2013e367 (2019).","journal-title":"Lancet Oncol."},{"key":"983_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2967\/jnumed.119.228684","volume":"61","author":"FWB van Leeuwen","year":"2020","unstructured":"van Leeuwen, F. W. B. et al. Trending: radioactive and fluorescent bimodal\/hybrid tracers as multiplexing solutions for surgical guidance. J. Nucl. Med. 61, 13\u201319 (2020).","journal-title":"J. Nucl. Med."},{"key":"983_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2533\/chimia.2020.939","volume":"74","author":"C M\u00fcller","year":"2020","unstructured":"M\u00fcller, C., B\u00e9h\u00e9, M., Geistlich, S., van der Meulen, N. P. & Schibli, R. Targeted radiotherapeutics from \u2018bench-to-bedside\u2019. Chimia 74, 939 (2020).","journal-title":"Chimia"},{"key":"983_CR17","doi-asserted-by":"publisher","first-page":"1034315","DOI":"10.3389\/fmed.2022.1034315","volume":"9","author":"M Shi","year":"2022","unstructured":"Shi, M. et al. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front. Med. 9, 1034315 (2022).","journal-title":"Front. Med."},{"key":"983_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros, G. et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of \u03b1-particle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311\u2013328 (2010).","journal-title":"J. Nucl. Med."},{"key":"983_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","volume":"4","author":"A Ku","year":"2019","unstructured":"Ku, A., Facca, V. J., Cai, Z. & Reilly, R. M. Auger electrons for cancer therapy \u2014 a review. EJNMMI Radiopharm. Chem. 4, 27 (2019).","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"983_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","volume":"132","author":"SM Seidlin","year":"1946","unstructured":"Seidlin, S. M., Marinelli, L. D. & Oshry, E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J. Am. Med. Assoc. 132, 838\u2013847 (1946).","journal-title":"J. Am. Med. Assoc."},{"key":"983_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros, G., Bodei, L., McDevitt, M. R. & Nedrow, J. R. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat. Rev. Drug Discov. 19, 589\u2013608 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"983_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson, S. M., Carrasquillo, J. A., Cheung, N. K. V. & Press, O. W. Radioimmunotherapy of human tumours. Nat. Rev. Cancer 15, 347\u2013360 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"983_CR23","first-page":"368","volume":"24","author":"M De Jong","year":"1997","unstructured":"De Jong, M. et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med. 24, 368\u2013371 (1997).","journal-title":"Eur. J. Nucl. Med."},{"key":"983_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/ijc.10952","volume":"104","author":"WAP Breeman","year":"2003","unstructured":"Breeman, W. A. P. et al. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model. Int. J. Cancer 104, 376\u2013379 (2003).","journal-title":"Int. J. Cancer"},{"key":"983_CR25","first-page":"5969","volume":"50","author":"JC Reubi","year":"1990","unstructured":"Reubi, J. C. et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 50, 5969\u20135977 (1990).","journal-title":"Cancer Res."},{"key":"983_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1210\/jcem-63-2-433","volume":"63","author":"JC Reubi","year":"1986","unstructured":"Reubi, J. C. et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J. Clin. Endocrinol. Metab. 63, 433\u2013438 (1986).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"983_CR27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s002590100639","volume":"28","author":"M Hofmann","year":"2001","unstructured":"Hofmann, M. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28, 1751\u20131757 (2001).","journal-title":"Eur. J. Nucl. Med."},{"key":"983_CR28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1023\/A:1011160913619","volume":"12","author":"C Waldherr","year":"2001","unstructured":"Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A. & Mueller-Brand, J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol. 12, 941\u2013945 (2001).","journal-title":"Ann. Oncol."},{"key":"983_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","volume":"30","author":"DJ Kwekkeboom","year":"2003","unstructured":"Kwekkeboom, D. J. et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging 30, 417\u2013422 (2003).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR30","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander, T. et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23, 4617\u20134624 (2017).","journal-title":"Clin. Cancer Res."},{"key":"983_CR31","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","volume":"69","author":"SM Hillier","year":"2009","unstructured":"Hillier, S. M. et al. Preclinical evaluation of novel glutamate\u2013urea\u2013lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 69, 6932\u20136940 (2009).","journal-title":"Cancer Res."},{"key":"983_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh, A. et al. Pet imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 40, 486\u2013495 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR33","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann, C. M. et al. Radiation dosimetry and first therapy results with a 124I\/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur. J. Nucl. Med. Mol. Imaging 41, 1280\u20131292 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer \u2014 updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. 77, 403\u2013417 (2020).","journal-title":"Eur. Urol."},{"key":"983_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2967\/jnumed.122.264298","volume":"64","author":"T Beyer","year":"2023","unstructured":"Beyer, T. et al. A 2022 international survey on the status of prostate cancer theranostics. J. Nucl. Med. 64, 47\u201353 (2023).","journal-title":"J. Nucl. Med."},{"key":"983_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/CCO.0000000000000439","volume":"30","author":"K Bouchelouche","year":"2018","unstructured":"Bouchelouche, K. & Choyke, P. L. Advances in PSMA positron emission tomography (PET) of prostate cancer. Curr. Opin. Oncol. 30, 189 (2018).","journal-title":"Curr. Opin. Oncol."},{"key":"983_CR37","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera, M. et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur. Urol. 70, 926\u2013937 (2016).","journal-title":"Eur. Urol."},{"key":"983_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467\u2013479 (2014).","journal-title":"Eur. Urol."},{"key":"983_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh, A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 41, 11\u201320 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR40","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber, M. et al. Evaluation of hybrid 68Ga\u2013PSMA Ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 56, 668\u2013674 (2015).","journal-title":"J. Nucl. Med."},{"key":"983_CR41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler, W. P. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 5, 856\u2013863 (2019).","journal-title":"JAMA Oncol."},{"key":"983_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06911-4","volume":"20","author":"A De Bruycker","year":"2020","unstructured":"De Bruycker, A. et al. PEACE V-salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer 20, 406 (2020).","journal-title":"BMC Cancer"},{"key":"983_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01553\/SUPPL_FILE\/PROTOCOL_JCO-25-01553.PDF","author":"AU Kishan","year":"2025","unstructured":"Kishan, A. U. et al. 177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-01553\/SUPPL_FILE\/PROTOCOL_JCO-25-01553.PDF (2025).","journal-title":"J. Clin. Oncol."},{"key":"983_CR44","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"983_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett, L. et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 25, 563\u2013571 (2024).","journal-title":"Lancet Oncol."},{"key":"983_CR46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad, A. A. et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267\u20131276 (2024).","journal-title":"Lancet Oncol."},{"key":"983_CR47","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris, M. J. et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227\u20131239 (2024).","journal-title":"Lancet"},{"key":"983_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","volume":"84","author":"DS Surasi","year":"2023","unstructured":"Surasi, D. S. et al. Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur. Urol. 84, 361\u2013370 (2023).","journal-title":"Eur. Urol."},{"key":"983_CR49","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.ijrobp.2022.07.585","volume":"114","author":"B Lowentritt","year":"2022","unstructured":"Lowentritt, B. impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Int. J. Radiat. Oncol. 114, S130\u2013S131 (2022).","journal-title":"Int. J. Radiat. Oncol."},{"key":"983_CR50","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04186819 (2025)."},{"key":"983_CR51","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04186845 (2025)."},{"key":"983_CR52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397, 797\u2013804 (2021).","journal-title":"Lancet"},{"key":"983_CR53","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","volume":"19","author":"L Bodei","year":"2022","unstructured":"Bodei, L., Herrmann, K., Sch\u00f6der, H., Scott, A. M. & Lewis, J. S. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat. Rev. Clin. Oncol. 19, 534\u2013550 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"983_CR54","doi-asserted-by":"publisher","first-page":"692436","DOI":"10.3389\/fmed.2021.692436","volume":"8","author":"JP Pouget","year":"2021","unstructured":"Pouget, J. P. & Constanzo, J. Revisiting the radiobiology of targeted alpha therapy. Front. Med. 8, 692436 (2021).","journal-title":"Front. Med."},{"key":"983_CR55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge, M. M. et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 25, 175\u2013183 (2024).","journal-title":"Lancet Oncol."},{"key":"983_CR56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker, B. et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur. Urol. 79, 343\u2013350 (2021).","journal-title":"Eur. Urol."},{"key":"983_CR57","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2967\/jnumed.125.269744","volume":"66","author":"A Wurzer","year":"2025","unstructured":"Wurzer, A. et al. [225Ac]Ac-PSMA I&T: a preclinical investigation on the fate of decay nuclides and their influence on dosimetry of salivary glands and kidneys. J. Nucl. Med. 66, 1964\u20131969 (2025).","journal-title":"J. Nucl. Med."},{"key":"983_CR58","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1200\/JCO.2023.41.16_suppl.4132","volume":"41","author":"M Morris","year":"2023","unstructured":"Morris, M. et al. ACTION-1 phase Ib\/3 trial of RYZ101 in somatostatin receptor subtype 2-expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: initial safety analysis. J. Clin. Oncol. 41, 4132\u20134132 (2023).","journal-title":"J. Clin. Oncol."},{"key":"983_CR59","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","volume":"63","author":"ES Delpassand","year":"2022","unstructured":"Delpassand, E. S. et al. Targeted \u03b1-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial. J. Nucl. Med. 63, 1326\u20131333 (2022).","journal-title":"J. Nucl. Med."},{"key":"983_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2967\/jnumed.123.266774","volume":"65","author":"R Zimmermann","year":"2024","unstructured":"Zimmermann, R. Is 212Pb really happening? The post-177Lu\/225Ac blockbuster? J. Nucl. Med. 65, 176\u2013177 (2024).","journal-title":"J. Nucl. Med."},{"key":"983_CR61","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2967\/jnumed.124.268345","volume":"66","author":"A Saidi","year":"2025","unstructured":"Saidi, A. et al. Side-by-side comparison of the in vivo performance of [212Pb]Pb-DOTAMTATE and other SSTR2-targeting compounds. J. Nucl. Med. 66, 391\u2013397 (2025).","journal-title":"J. Nucl. Med."},{"key":"983_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-025-00763-2","volume":"12","author":"D K\u00e4stner","year":"2025","unstructured":"K\u00e4stner, D. et al. Gamma camera imaging characteristics of 203\/212Pb as a theragnostic pair for targeted alpha therapy: a feasibility study. EJNMMI Phys. 12, 50 (2025).","journal-title":"EJNMMI Phys."},{"key":"983_CR63","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","volume":"53","author":"M Fani","year":"2012","unstructured":"Fani, M. et al. Unexpected sensitivity of SST2 antagonists to N-terminal radiometal modifications. J. Nucl. Med. 53, 1481\u20131489 (2012).","journal-title":"J. Nucl. Med."},{"key":"983_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/med.70008","volume":"46","author":"M M\u00fcller","year":"2026","unstructured":"M\u00fcller, M. et al. Astatine-211 \u2014 towards in vivo stable astatine-211 labeled radiopharmaceuticals and their (pre)clinical applications. Med. Res. Rev. 46, 203\u2013237 (2026).","journal-title":"Med. Res. Rev."},{"key":"983_CR65","doi-asserted-by":"publisher","first-page":"1076210","DOI":"10.3389\/fmed.2022.1076210","volume":"9","author":"P Albertsson","year":"2023","unstructured":"Albertsson, P. et al. Astatine-211 based radionuclide therapy: current clinical trial landscape. Front. Med. 9, 1076210 (2023).","journal-title":"Front. Med."},{"key":"983_CR66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213\u2013223 (2013).","journal-title":"N. Engl. J. Med."},{"key":"983_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105905","volume":"10","author":"A Minchom","year":"2025","unstructured":"Minchom, A. et al. First-in-human study of a thorium-227-labeled mesothelin-targeting antibody\u2013chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. ESMO Open 10, 105905 (2025).","journal-title":"ESMO Open"},{"key":"983_CR68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.nucmedbio.2021.03.002","volume":"96\u201397","author":"G Pirovano","year":"2021","unstructured":"Pirovano, G., Wilson, T. C. & Reiner, T. Auger: the future of precision medicine. Nucl. Med. Biol. 96\u201397, 50\u201353 (2021).","journal-title":"Nucl. Med. Biol."},{"key":"983_CR69","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","volume":"49","author":"F Borgna","year":"2022","unstructured":"Borgna, F. et al. Combination of terbium-161 with somatostatin receptor antagonists \u2014 a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur. J. Nucl. Med. Mol. Imaging 49, 1113\u20131126 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR70","doi-asserted-by":"publisher","first-page":"1352615","DOI":"10.3389\/fimmu.2024.1352615","volume":"15","author":"S Dziadek","year":"2024","unstructured":"Dziadek, S. et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Front. Immunol. 15, 1352615 (2024).","journal-title":"Front. Immunol."},{"key":"983_CR71","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev, A. et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J. Nucl. Med. 60, 1421\u20131429 (2019).","journal-title":"J. Nucl. Med."},{"key":"983_CR72","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.122.264544","volume":"64","author":"Y Pang","year":"2023","unstructured":"Pang, Y. et al. PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study. J. Nucl. Med. 64, 386\u2013394 (2023).","journal-title":"J. Nucl. Med."},{"key":"983_CR73","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski, D. et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur. J. Nucl. Med. Mol. Imaging 49, 3651\u20133667 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel, F. L. et al. FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J. Nucl. Med. 62, 201\u2013207 (2021).","journal-title":"J. Nucl. Med."},{"key":"983_CR75","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","volume":"64","author":"M Ora","year":"2023","unstructured":"Ora, M. et al. Fibroblast activation protein inhibitor-based radionuclide therapies: current status and future directions. J. Nucl. Med. 64, 1001\u20131008 (2023).","journal-title":"J. Nucl. Med."},{"key":"983_CR76","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner, T. et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J. Nucl. Med. 59, 1415\u20131422 (2018).","journal-title":"J. Nucl. Med."},{"key":"983_CR77","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/cancers15061889","volume":"15","author":"M Martin","year":"2023","unstructured":"Martin, M. et al. Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics. Cancers 15, 1889 (2023).","journal-title":"Cancers"},{"key":"983_CR78","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3390\/diagnostics13122018","volume":"13","author":"KR Chandekar","year":"2023","unstructured":"Chandekar, K. R., Prashanth, A., Vinjamuri, S. & Kumar, R. FAPI PET\/CT imaging \u2014 an updated review. Diagnostics 13, 2018 (2023).","journal-title":"Diagnostics"},{"key":"983_CR79","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.122.265003","volume":"64","author":"R Kashyap","year":"2023","unstructured":"Kashyap, R. & Kumar, A. S. R. Could FAP-targeted molecular imaging replace 18F-FDG for standard-of-care oncologic PET? J. Nucl. Med. 64, 623\u2013624 (2023).","journal-title":"J. Nucl. Med."},{"key":"983_CR80","doi-asserted-by":"publisher","DOI":"10.2967\/JNUMED.125.271317","author":"L Li","year":"2026","unstructured":"Li, L. et al. Initial results and clinical experiences of [177Lu]Lu-FAP-2286 for pleural metastases: a single-center retrospective study. J. Nucl. Med. https:\/\/doi.org\/10.2967\/JNUMED.125.271317 (2026).","journal-title":"J. Nucl. Med."},{"key":"983_CR81","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/ph14121212","volume":"14","author":"S Ballal","year":"2021","unstructured":"Ballal, S. et al. First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2. Pharmaceuticals 14, 1212 (2021).","journal-title":"Pharmaceuticals"},{"key":"983_CR82","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","volume":"31","author":"H Fu","year":"2025","unstructured":"Fu, H. et al. 177Lu-LNC1004 radioligand therapy in patients with end-stage metastatic cancers: a single-center, single-arm, phase II study. Clin. Cancer Res. 31, 1415\u20131426 (2025).","journal-title":"Clin. Cancer Res."},{"key":"983_CR83","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2967\/jnumed.124.267547","volume":"66","author":"RJ Hicks","year":"2025","unstructured":"Hicks, R. J. Are FAP theranostics really happening? Will radiochemistry or biology win? J. Nucl. Med. 66, 497\u2013499 (2025).","journal-title":"J. Nucl. Med."},{"key":"983_CR84","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06710756 (2026)."},{"key":"983_CR85","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06911489 (2026)."},{"key":"983_CR86","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","volume":"130","author":"EN Hoogenboezem","year":"2018","unstructured":"Hoogenboezem, E. N. & Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 130, 73\u201389 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"983_CR87","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2967\/jnumed.116.182097","volume":"58","author":"H Chen","year":"2017","unstructured":"Chen, H. et al. Novel \u201cadd-on\u201d molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents. J. Nucl. Med. 58, 590\u2013597 (2017).","journal-title":"J. Nucl. Med."},{"key":"983_CR88","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","volume":"50","author":"X Wen","year":"2023","unstructured":"Wen, X. et al. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur. J. Nucl. Med. Mol. Imaging 50, 2846\u20132860 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR89","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","volume":"29","author":"H Fu","year":"2023","unstructured":"Fu, H. et al. Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study. Clin. Cancer Res. 29, 4740\u20134750 (2023).","journal-title":"Clin. Cancer Res."},{"key":"983_CR90","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/thno.68182","volume":"12","author":"X Wen","year":"2022","unstructured":"Wen, X. et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 12, 422\u2013433 (2022).","journal-title":"Theranostics"},{"key":"983_CR91","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.7150\/thno.25919","volume":"8","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. Response to single low-dose 177Lu-DOTA-EB-TATE treatment in patients with advanced neuroendocrine neoplasm: a prospective pilot study. Theranostics 8, 3308 (2018).","journal-title":"Theranostics"},{"key":"983_CR92","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1021\/acs.molpharmaceut.4c00369","volume":"21","author":"Z Qiao","year":"2024","unstructured":"Qiao, Z. et al. Effect of ibuprofen as an albumin binder on melanoma-targeting properties of 177Lu-labeled ibuprofen-conjugated alpha-melanocyte-stimulating hormone peptides. Mol. Pharm. 21, 4004\u20134011 (2024).","journal-title":"Mol. Pharm."},{"key":"983_CR93","doi-asserted-by":"publisher","first-page":"116919","DOI":"10.1016\/j.ejmech.2024.116919","volume":"279","author":"T Ye","year":"2024","unstructured":"Ye, T. et al. 211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma. Eur. J. Med. Chem. 279, 116919 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"983_CR94","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","volume":"49","author":"VJ Tschan","year":"2022","unstructured":"Tschan, V. J. et al. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 49, 3639\u20133650 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR95","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf, C., Glatting, G., Chiesa, C., Lind\u00e9n, O. & Flux, G. EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur. J. Nucl. Med. Mol. Imaging 37, 1238\u20131250 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR96","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang, J. et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 46, 148\u2013158 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR97","doi-asserted-by":"publisher","unstructured":"Staudt, M. et al. Pretargeted theranostics. In Theranostics \u2014 An Old Concept in New Clothing https:\/\/doi.org\/10.5772\/INTECHOPEN.95567 (2021).","DOI":"10.5772\/INTECHOPEN.95567"},{"key":"983_CR98","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","volume":"63","author":"SM Cheal","year":"2022","unstructured":"Cheal, S. M., Chung, S. K., Vaughn, B. A., Cheung, N. K. V. & Larson, S. M. Pretargeting: a path forward for radioimmunotherapy. J. Nucl. Med. 63, 1302\u20131315 (2022).","journal-title":"J. Nucl. Med."},{"key":"983_CR99","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2967\/jnumed.117.193250","volume":"58","author":"SM Cheal","year":"2017","unstructured":"Cheal, S. M. et al. Curative multicycle radioimmunotherapy monitored by quantitative SPECT\/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer. J. Nucl. Med. 58, 1735\u20131742 (2017).","journal-title":"J. Nucl. Med."},{"key":"983_CR100","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","volume":"630","author":"XY Cui","year":"2024","unstructured":"Cui, X. Y. et al. Covalent targeted radioligands potentiate radionuclide therapy. Nature 630, 206\u2013213 (2024).","journal-title":"Nature"},{"key":"983_CR101","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/028418600430789","volume":"39","author":"MI Koukourakis","year":"2000","unstructured":"Koukourakis, M. I. et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas \u2014 rationale for combination with radiotherapy. Acta Oncol. 39, 207\u2013211 (2000).","journal-title":"Acta Oncol."},{"key":"983_CR102","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","volume":"23","author":"H Lee","year":"2017","unstructured":"Lee, H. et al. 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin. Cancer Res. 23, 4190\u20134202 (2017).","journal-title":"Clin. Cancer Res."},{"key":"983_CR103","doi-asserted-by":"publisher","first-page":"2201043","DOI":"10.1002\/adma.202201043","volume":"34","author":"IHC Miedema","year":"2022","unstructured":"Miedema, I. H. C. et al. PET\u2013CT imaging of polymeric nanoparticle tumor accumulation in patients. Adv. Mater. 34, 2201043 (2022).","journal-title":"Adv. Mater."},{"key":"983_CR104","first-page":"20180365","volume":"92","author":"F Lux","year":"2019","unstructured":"Lux, F. et al. AGuiX from bench to bedside-transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br. J. Radiol. 92, 20180365 (2019).","journal-title":"Br. J. Radiol."},{"key":"983_CR105","doi-asserted-by":"publisher","first-page":"11838","DOI":"10.1038\/ncomms11838","volume":"7","author":"C P\u00e9rez-Medina","year":"2016","unstructured":"P\u00e9rez-Medina, C. et al. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nat. Commun. 7, 11838 (2016).","journal-title":"Nat. Commun."},{"key":"983_CR106","doi-asserted-by":"publisher","first-page":"314ra183","DOI":"10.1126\/scitranslmed.aac6522","volume":"7","author":"MA Miller","year":"2015","unstructured":"Miller, M. A. et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci. Transl. Med. 7, 314ra183 (2015).","journal-title":"Sci. Transl. Med."},{"key":"983_CR107","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.220022","volume":"5","author":"H Ravi","year":"2023","unstructured":"Ravi, H. et al. Pretherapy ferumoxytol-enhanced MRI to predict response to liposomal irinotecan in metastatic breast cancer. Radiol. Imaging Cancer 5, e220022 (2023).","journal-title":"Radiol. Imaging Cancer"},{"key":"983_CR108","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2012.05.007","volume":"163","author":"S Fokong","year":"2012","unstructured":"Fokong, S. et al. Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. J. Control. Release 163, 75\u201381 (2012).","journal-title":"J. Control. Release"},{"key":"983_CR109","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nnano.2015.25","volume":"10","author":"E Huynh","year":"2015","unstructured":"Huynh, E. et al. In situ conversion of porphyrin microbubbles to nanoparticles for multimodality imaging. Nat. Nanotechnol. 10, 325\u2013332 (2015).","journal-title":"Nat. Nanotechnol."},{"key":"983_CR110","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/17425247.2018.1547279","volume":"15","author":"S Snipstad","year":"2018","unstructured":"Snipstad, S. et al. Sonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translation. Expert Opin. Drug Deliv. 15, 1249\u20131261 (2018).","journal-title":"Expert Opin. Drug Deliv."},{"key":"983_CR111","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/adfm.201401199","volume":"25","author":"T Lammers","year":"2015","unstructured":"Lammers, T. et al. Theranostic USPIO-loaded microbubbles for mediating and monitoring blood-brain barrier permeation. Adv. Funct. Mater. 25, 36\u201343 (2015).","journal-title":"Adv. Funct. Mater."},{"key":"983_CR112","doi-asserted-by":"publisher","first-page":"20220767","DOI":"10.1259\/bjr.20220767","volume":"96","author":"TF Hsu","year":"2023","unstructured":"Hsu, T. F. et al. Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy. Br. J. Radiol. 96, 20220767 (2023).","journal-title":"Br. J. Radiol."},{"key":"983_CR113","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1053\/j.semnuclmed.2019.01.008","volume":"49","author":"MTM Reinders","year":"2019","unstructured":"Reinders, M. T. M., Smits, M. L. J., van Roekel, C. & Braat, A. J. A. T. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin. Nucl. Med. 49, 237\u2013243 (2019).","journal-title":"Semin. Nucl. Med."},{"key":"983_CR114","doi-asserted-by":"publisher","first-page":"20150943","DOI":"10.1259\/bjr.20150943","volume":"89","author":"AKT Tong","year":"2016","unstructured":"Tong, A. K. T. et al. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br. J. Radiol. 89, 20150943 (2016).","journal-title":"Br. J. Radiol."},{"key":"983_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-82095-6","volume":"11","author":"L Dallet","year":"2021","unstructured":"Dallet, L., Stanicki, D., Voisin, P., Miraux, S. & Ribot, E. J. Micron-sized iron oxide particles for both MRI cell tracking and magnetic fluid hyperthermia treatment. Sci. Rep. 11, 1\u201313 (2021).","journal-title":"Sci. Rep."},{"key":"983_CR116","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1021\/acschemneuro.8b00652","volume":"10","author":"R Gupta","year":"2019","unstructured":"Gupta, R. & Sharma, D. Evolution of magnetic hyperthermia for glioblastoma multiforme therapy. ACS Chem. Neurosci. 10, 1157\u20131172 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"983_CR117","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1080\/02656736.2018.1430867","volume":"34","author":"K Mahmoudi","year":"2018","unstructured":"Mahmoudi, K., Bouras, A., Bozec, D., Ivkov, R. & Hadjipanayis, C. Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy\u2019s history, efficacy and application in humans. Int. J. Hyperthermia 34, 1316\u20131328 (2018).","journal-title":"Int. J. Hyperthermia"},{"key":"983_CR118","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.addr.2018.10.013","volume":"138","author":"S Pinel","year":"2019","unstructured":"Pinel, S., Thomas, N., Boura, C. & Barberi-Heyob, M. Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment. Adv. Drug Deliv. Rev. 138, 344\u2013357 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"983_CR119","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-018-03005-x","volume":"141","author":"O Grauer","year":"2019","unstructured":"Grauer, O. et al. Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. J. Neurooncol. 141, 83\u201394 (2019).","journal-title":"J. Neurooncol."},{"key":"983_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-023-02938-0","volume":"43","author":"J Da Silva","year":"2024","unstructured":"Da Silva, J. et al. Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization. J. Exp. Clin. Cancer Res. 43, 1\u201322 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"983_CR121","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ijrobp.2021.06.041","volume":"111","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. Radiation therapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects. Int. J. Radiat. Oncol. 111, 647\u2013657 (2021).","journal-title":"Int. J. Radiat. Oncol."},{"key":"983_CR122","doi-asserted-by":"publisher","first-page":"1022011","DOI":"10.3389\/fimmu.2022.1022011","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front. Immunol. 13, 1022011 (2022).","journal-title":"Front. Immunol."},{"key":"983_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-022-02615-w","volume":"22","author":"A Darmon","year":"2022","unstructured":"Darmon, A. et al. Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire. Cancer Cell Int. 22, 1\u201314 (2022).","journal-title":"Cancer Cell Int."},{"key":"983_CR124","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ijrobp.2022.07.001","volume":"114","author":"S Bonvalot","year":"2022","unstructured":"Bonvalot, S. et al. Final safety and health-related quality of life results of the phase 2\/3 Act.In.Sarc study with preoperative NBTXR3 plus radiation therapy versus radiation therapy in locally advanced soft-tissue sarcoma. Int. J. Radiat. Oncol. 114, 422\u2013432 (2022).","journal-title":"Int. J. Radiat. Oncol."},{"key":"983_CR125","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.2147\/IJN.S301182","volume":"16","author":"P Zhang","year":"2021","unstructured":"Zhang, P. et al. Nbtxr3 radiotherapy-activated functionalized hafnium oxide nanoparticles show efficient antitumor effects across a large panel of human cancer models. Int. J. Nanomed. 16, 2761\u20132773 (2021).","journal-title":"Int. J. Nanomed."},{"key":"983_CR126","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1078-0432.CCR-16-1297","volume":"23","author":"S Bonvalot","year":"2017","unstructured":"Bonvalot, S. et al. First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas. Clin. Cancer Res. 23, 908\u2013917 (2017).","journal-title":"Clin. Cancer Res."},{"key":"983_CR127","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2021.01.007","volume":"146","author":"C Hoffmann","year":"2021","unstructured":"Hoffmann, C. et al. Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. Eur. J. Cancer 146, 135\u2013144 (2021).","journal-title":"Eur. J. Cancer"},{"key":"983_CR128","doi-asserted-by":"crossref","first-page":"A714","DOI":"10.1136\/jitc-2021-004348","volume":"10","author":"C Shen","year":"2022","unstructured":"Shen, C. et al. 684NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100). J. Immunother. Cancer 10, A714 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"983_CR129","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","volume":"20","author":"S Bonvalot","year":"2019","unstructured":"Bonvalot, S. et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial. Lancet Oncol. 20, 1148\u20131159 (2019).","journal-title":"Lancet Oncol."},{"key":"983_CR130","doi-asserted-by":"publisher","unstructured":"Mariussi, M. et al. Selective internal radiation therapy combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma: a systematic review and single-arm meta-analysis. Dig. Dis. Sci.\u00a0https:\/\/doi.org\/10.1007\/S10620-025-09139-Z (2025).","DOI":"10.1007\/S10620-025-09139-Z"},{"key":"983_CR131","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.cpet.2024.03.010","volume":"19","author":"K Ramdhani","year":"2024","unstructured":"Ramdhani, K., Lam, M. G. E. H., Braat, A. J. A. T., Smits, M. L. J. & El-Haddad, G. Hepatic radioembolization: a multistep theragnostic procedure. PET Clin. 19, 431\u2013446 (2024).","journal-title":"PET Clin."},{"key":"983_CR132","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.3390\/cancers17243889","volume":"17","author":"CCI Schneider","year":"2025","unstructured":"Schneider, C. C. I. et al. High-dose transarterial radioembolization of hepatic metastases using Yttrium-90 resin microspheres. Cancers 17, 3889 (2025).","journal-title":"Cancers"},{"key":"983_CR133","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3390\/jcm12030918","volume":"12","author":"MM Welling","year":"2023","unstructured":"Welling, M. M. et al. Microspheres as a carrier system for therapeutic embolization procedures: achievements and advances. J. Clin. Med. 12, 918 (2023).","journal-title":"J. Clin. Med."},{"key":"983_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2022.07.019","volume":"149","author":"A P\u00e9rez-L\u00f3pez","year":"2022","unstructured":"P\u00e9rez-L\u00f3pez, A., Mart\u00edn-Sabroso, C., G\u00f3mez-L\u00e1zaro, L., Torres-Su\u00e1rez, A. I. & Aparicio-Blanco, J. Embolization therapy with microspheres for the treatment of liver cancer: state-of-the-art of clinical translation. Acta Biomater. 149, 1\u201315 (2022).","journal-title":"Acta Biomater."},{"key":"983_CR135","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijrobp.2006.12.022","volume":"68","author":"TG Purdie","year":"2007","unstructured":"Purdie, T. G. et al. Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position. Int. J. Radiat. Oncol. 68, 243\u2013252 (2007).","journal-title":"Int. J. Radiat. Oncol."},{"key":"983_CR136","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00066-020-01604-0","volume":"196","author":"F Putz","year":"2020","unstructured":"Putz, F. et al. Magnetic resonance imaging for brain stereotactic radiotherapy: a review of requirements and pitfalls. Strahlenther. Onkol. 196, 444\u2013456 (2020).","journal-title":"Strahlenther. Onkol."},{"key":"983_CR137","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drup.2016.06.003","volume":"27","author":"R Blau","year":"2016","unstructured":"Blau, R., Krivitsky, A., Epshtein, Y. & Satchi-Fainaro, R. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine? Drug Resist. Updat. 27, 39\u201358 (2016).","journal-title":"Drug Resist. Updat."},{"key":"983_CR138","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","volume":"14","author":"R van der Meel","year":"2019","unstructured":"van der Meel, R. et al. Smart cancer nanomedicine. Nat. Nanotechnol. 14, 1007\u20131017 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"983_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-10829-y","volume":"23","author":"E Thivat","year":"2023","unstructured":"Thivat, E. et al. Phase I\/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). BMC Cancer 23, 1\u201310 (2023).","journal-title":"BMC Cancer"},{"key":"983_CR140","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","volume":"160","author":"C Verry","year":"2021","unstructured":"Verry, C. et al. Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiother. Oncol. 160, 159\u2013165 (2021).","journal-title":"Radiother. Oncol."},{"key":"983_CR141","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nmat3776","volume":"12","author":"S Mura","year":"2013","unstructured":"Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12, 991\u20131003 (2013).","journal-title":"Nat. Mater."},{"key":"983_CR142","doi-asserted-by":"publisher","first-page":"113847","DOI":"10.1016\/j.addr.2021.113847","volume":"177","author":"S Snipstad","year":"2021","unstructured":"Snipstad, S. et al. Ultrasound and microbubbles to beat barriers in tumors: improving delivery of nanomedicine. Adv. Drug Deliv. Rev. 177, 113847 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"983_CR143","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(25)00492-9","volume":"26","author":"GF Woodworth","year":"2025","unstructured":"Woodworth, G. F. et al. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 26, 1651\u20131664 (2025).","journal-title":"Lancet Oncol."},{"key":"983_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov\u00a0https:\/\/clinicaltrials.gov\/study\/NCT03551249 (2026)."},{"key":"983_CR145","unstructured":"US National Library of Medicine. ClinicalTrials.gov\u00a0https:\/\/clinicaltrials.gov\/study\/NCT03616860 (2024)."},{"key":"983_CR146","unstructured":"Hofland, P. Japan approves cetuximab saratolacan in unresectable locally advanced\/recurrent head & neck cancer. Onco\u2019Zine https:\/\/www.oncozine.com\/japan-approves-cetuximab-saratolacan-in-unresectable-locally-advanced-recurrent-head-neck-cancer\/ (2020)."},{"key":"983_CR147","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","volume":"52","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi, H. & Choyke, P. L. Near-infrared photoimmunotherapy of cancer. Acc. Chem. Res. 52, 2332\u20132339 (2019).","journal-title":"Acc. Chem. Res."},{"key":"983_CR148","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03769506 (2025)."},{"key":"983_CR149","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/hed.26885","volume":"43","author":"DM Cognetti","year":"2021","unstructured":"Cognetti, D. M. et al. Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck 43, 3875\u20133887 (2021).","journal-title":"Head Neck"},{"key":"983_CR150","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1007\/s10147-021-01960-6","volume":"26","author":"M Tahara","year":"2021","unstructured":"Tahara, M. et al. A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. Int. J. Clin. Oncol. 26, 1812\u20131821 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"983_CR151","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04791228 (2025)."},{"key":"983_CR152","doi-asserted-by":"publisher","first-page":"101202","DOI":"10.1016\/j.adro.2023.101202","volume":"8","author":"D Sung","year":"2023","unstructured":"Sung, D., Sanchez, A. & Tward, J. D. Successful salvage brachytherapy after infusion of gold Auroshell nanoshells for localized prostate cancer in a human patient. Adv. Radiat. Oncol. 8, 101202 (2023).","journal-title":"Adv. Radiat. Oncol."},{"key":"983_CR153","doi-asserted-by":"publisher","first-page":"18590","DOI":"10.1073\/pnas.1906929116","volume":"116","author":"AR Rastinehad","year":"2019","unstructured":"Rastinehad, A. R. et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proc. Natl Acad. Sci. USA 116, 18590\u201318596 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"983_CR154","first-page":"1","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. Smart nanoparticles for cancer therapy. Signal. Transduct. Target. Ther. 8, 1\u201328 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"983_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01926-y","volume":"21","author":"B Bortot","year":"2023","unstructured":"Bortot, B. et al. Image-guided cancer surgery: a narrative review on imaging modalities and emerging nanotechnology strategies. J. Nanobiotechnol. 21, 155 (2023).","journal-title":"J. Nanobiotechnol."},{"key":"983_CR156","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s44222-022-00017-1","volume":"1","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Fluorescence image-guided tumour surgery. Nat. Rev. Bioeng. 1, 161\u2013179 (2023).","journal-title":"Nat. Rev. Bioeng."},{"key":"983_CR157","doi-asserted-by":"publisher","first-page":"1904329","DOI":"10.1002\/adma.201904329","volume":"31","author":"C Wang","year":"2019","unstructured":"Wang, C. et al. Advanced nanotechnology leading the way to multimodal imaging-guided precision surgical therapy. Adv. Mater. 31, 1904329 (2019).","journal-title":"Adv. Mater."},{"key":"983_CR158","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3390\/cancers17122019","volume":"17","author":"M Elliot","year":"2025","unstructured":"Elliot, M. et al. Fluorescence guidance in glioma surgery: a narrative review of current evidence and the drive towards objective margin differentiation. Cancers 17, 2019 (2025).","journal-title":"Cancers"},{"key":"983_CR159","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-021-00548-3","volume":"19","author":"JSD Mieog","year":"2021","unstructured":"Mieog, J. S. D. et al. Fundamentals and developments in fluorescence-guided cancer surgery. Nat. Rev. Clin. Oncol. 19, 9\u201322 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"983_CR160","doi-asserted-by":"publisher","first-page":"E1420","DOI":"10.1097\/TXD.0000000000001420","volume":"8","author":"F Kneifel","year":"2022","unstructured":"Kneifel, F. et al. Hyperspectral imaging for viability assessment of human liver allografts during normothermic machine perfusion. Transplant. Direct 8, E1420 (2022).","journal-title":"Transplant. Direct"},{"key":"983_CR161","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ymthe.2017.10.016","volume":"26","author":"JD Predina","year":"2018","unstructured":"Predina, J. D. et al. Identification of a folate receptor-targeted near-infrared molecular contrast agent to localize pulmonary adenocarcinomas. Mol. Ther. 26, 390\u2013403 (2018).","journal-title":"Mol. Ther."},{"key":"983_CR162","doi-asserted-by":"publisher","first-page":"9637","DOI":"10.1021\/acs.jmedchem.8b01115","volume":"61","author":"SM Mahalingam","year":"2018","unstructured":"Mahalingam, S. M. et al. Evaluation of novel tumor-targeted near-infrared probe for fluorescence-guided surgery of cancer. J. Med. Chem. 61, 9637\u20139646 (2018).","journal-title":"J. Med. Chem."},{"key":"983_CR163","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1158\/1078-0432.CCR-15-2640","volume":"22","author":"CES Hoogstins","year":"2016","unstructured":"Hoogstins, C. E. S. et al. A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer. Clin. Cancer Res. 22, 2929\u20132938 (2016).","journal-title":"Clin. Cancer Res."},{"key":"983_CR164","doi-asserted-by":"publisher","first-page":"674083","DOI":"10.3389\/fonc.2021.674083","volume":"11","author":"S Hernandez Vargas","year":"2021","unstructured":"Hernandez Vargas, S. et al. Receptor-targeted fluorescence-guided surgery with low molecular weight agents. Front. Oncol. 11, 674083 (2021).","journal-title":"Front. Oncol."},{"key":"983_CR165","doi-asserted-by":"publisher","first-page":"320ra4","DOI":"10.1126\/scitranslmed.aad0293","volume":"8","author":"MJ Whitley","year":"2016","unstructured":"Whitley, M. J. et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci. Transl. Med. 8, 320ra4 (2016).","journal-title":"Sci. Transl. Med."},{"key":"983_CR166","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-021-06106-w","volume":"187","author":"CR Lanahan","year":"2021","unstructured":"Lanahan, C. R. et al. Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery. Breast Cancer Res. Treat. 187, 145\u2013153 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"983_CR167","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03321929 (2023)."},{"key":"983_CR168","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02438358 (2023)."},{"key":"983_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-019-0703-1","volume":"12","author":"ER Malone","year":"2020","unstructured":"Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L. & Siu, L. L. Molecular profiling for precision cancer therapies. Genome Med. 12, 1\u201319 (2020).","journal-title":"Genome Med."},{"key":"983_CR170","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/s24010037","volume":"24","author":"S Das","year":"2023","unstructured":"Das, S., Dey, M. K., Devireddy, R. & Gartia, M. R. Biomarkers in cancer detection, diagnosis, and prognosis. Sensors 24, 37 (2023).","journal-title":"Sensors"},{"key":"983_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151654","volume":"11","author":"M Itonaga","year":"2016","unstructured":"Itonaga, M. et al. Novel methodology for rapid detection of KRAS mutation using PNA\u2013LNA mediated loop-mediated isothermal amplification. PLoS ONE 11, e0151654 (2016).","journal-title":"PLoS ONE"},{"key":"983_CR172","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2353\/jmoldx.2008.080024","volume":"10","author":"K Tatsumi","year":"2008","unstructured":"Tatsumi, K. et al. Rapid screening assay for KRAS mutations by the modified smart amplification process. J. Mol. Diagn. 10, 520\u2013526 (2008).","journal-title":"J. Mol. Diagn."},{"key":"983_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107277","volume":"26","author":"S Liao","year":"2023","unstructured":"Liao, S. et al. Emerging biomedical imaging-based companion diagnostics for precision medicine. iScience 26, 107277 (2023).","journal-title":"iScience"},{"key":"983_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-024-03559-w","volume":"22","author":"N Jin","year":"2024","unstructured":"Jin, N. et al. Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study. BMC Med. 22, 1\u201316 (2024).","journal-title":"BMC Med."},{"key":"983_CR175","first-page":"1","volume":"8","author":"H Cheng","year":"2024","unstructured":"Cheng, H. et al. Illuminating the future of precision cancer surgery with fluorescence imaging and artificial intelligence convergence. npj Precis. Oncol. 8, 1\u201314 (2024).","journal-title":"npj Precis. Oncol."},{"key":"983_CR176","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/ijtm5030040","volume":"5","author":"A Blosse","year":"2025","unstructured":"Blosse, A. et al. Fluorescence-guided surgery in head and neck squamous cell carcinoma (HNSCC). Int. J. Transl. Med. 5, 5 (2025).","journal-title":"Int. J. Transl. Med."},{"key":"983_CR177","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05499065 (2025)."},{"key":"983_CR178","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3390\/bioengineering10121435","volume":"10","author":"L Pinto-Coelho","year":"2023","unstructured":"Pinto-Coelho, L. How artificial intelligence is shaping medical imaging technology: a survey of innovations and applications. Bioengineering 10, 1435 (2023).","journal-title":"Bioengineering"},{"key":"983_CR179","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/0146645320940827","volume":"49","author":"CH McCollough","year":"2020","unstructured":"McCollough, C. H. & Leng, S. Use of artificial intelligence in computed tomography dose optimisation. Ann. ICRP 49, 113\u2013125 (2020).","journal-title":"Ann. ICRP"},{"key":"983_CR180","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.3390\/cancers15092573","volume":"15","author":"R Paudyal","year":"2023","unstructured":"Paudyal, R. et al. Artificial intelligence in CT and MR imaging for oncological applications. Cancers 15, 2573 (2023).","journal-title":"Cancers"},{"key":"983_CR181","first-page":"1321","volume":"5","author":"S Marletta","year":"2024","unstructured":"Marletta, S., Rizzo, A., Spoto, G. & Falzone, L. Predictive and prognostic biomarkers in cancer: towards the precision medicine era. Open Explor. 5, 1321\u20131325 (2024).","journal-title":"Open Explor."},{"key":"983_CR182","doi-asserted-by":"publisher","first-page":"491207","DOI":"10.3389\/fonc.2019.01476","volume":"9","author":"S Fakurnejad","year":"2020","unstructured":"Fakurnejad, S. et al. Intraoperative molecular imaging for ex vivo assessment of peripheral margins in oral squamous cell carcinoma. Front. Oncol. 9, 491207 (2020).","journal-title":"Front. Oncol."},{"key":"983_CR183","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2967\/jnumed.119.240424","volume":"61","author":"C Darr","year":"2020","unstructured":"Darr, C. et al. Intraoperative 68Ga-PSMA Cerenkov luminescence imaging for surgical margins in radical prostatectomy: a feasibility study. J. Nucl. Med. 61, 1500\u20131506 (2020).","journal-title":"J. Nucl. Med."},{"key":"983_CR184","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1007\/s00259-023-06545-1","volume":"51","author":"J Vonk","year":"2024","unstructured":"Vonk, J. et al. Towards molecular imaging-guided intervention theatres in oncology. Eur. J. Nucl. Med. Mol. Imaging 51, 3055\u20133060 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"983_CR185","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41551-021-00808-8","volume":"6","author":"FJ Voskuil","year":"2021","unstructured":"Voskuil, F. J. et al. Intraoperative imaging in pathology-assisted surgery. Nat. Biomed. Eng. 6, 503\u2013514 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"983_CR186","doi-asserted-by":"publisher","first-page":"82S","DOI":"10.2967\/jnmt.125.270251","volume":"53","author":"GM Currie","year":"2025","unstructured":"Currie, G. M. & Rohren, E. The role of artificial intelligence in theranostics. J. Nucl. Med. Technol. 53, 82S\u201391S (2025).","journal-title":"J. Nucl. Med. Technol."},{"key":"983_CR187","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41565-024-01753-8","volume":"19","author":"L Rao","year":"2024","unstructured":"Rao, L., Yuan, Y., Shen, X., Yu, G. & Chen, X. Designing nanotheranostics with machine learning. Nat. Nanotechnol. 19, 1769\u20131781 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"983_CR188","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ph12030114","volume":"12","author":"U Hennrich","year":"2019","unstructured":"Hennrich, U. & Kopka, K. Lutathera: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals 12, 12 (2019).","journal-title":"Pharmaceuticals"},{"key":"983_CR189","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05477576 (2026)."},{"key":"983_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02609737 (2022)."},{"key":"983_CR191","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","volume":"62","author":"RP Baum","year":"2021","unstructured":"Baum, R. P., Zhang, J., Schuchardt, C., M\u00fcller, D. & M\u00e4cke, H. First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy. J. Nucl. Med. 62, 1571\u20131581 (2021).","journal-title":"J. Nucl. Med."},{"key":"983_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05359146 (2024)."},{"key":"983_CR193","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03308682 (2017)."},{"key":"983_CR194","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03478358 (2022)."},{"key":"983_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05475210 (2024)."},{"key":"983_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04023331 (2025)."},{"key":"983_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03936426 (2020)."},{"key":"983_CR198","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05153772 (2026)."},{"key":"983_CR199","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03049189 (2026)."},{"key":"983_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05636618 (2026)."},{"key":"983_CR201","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah, J. et al. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 29, 1651\u20131657 (2023).","journal-title":"Clin. Cancer Res."},{"key":"983_CR202","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06855277 (2026)."},{"key":"983_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06780670 (2026)."},{"key":"983_CR204","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2967\/jnumed.118.218917","volume":"60","author":"H Rathke","year":"2019","unstructured":"Rathke, H. et al. Dosimetry estimate and initial clinical experience with 90Y-PSMA-617. J. Nucl. Med. 60, 806\u2013811 (2019).","journal-title":"J. Nucl. Med."},{"key":"983_CR205","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04647526 (2026)."},{"key":"983_CR206","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05204927 (2025)."},{"key":"983_CR207","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07611110 (2026)."},{"key":"983_CR208","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05413850 (2026)."},{"key":"983_CR209","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05725070 (2023)."},{"key":"983_CR210","unstructured":"Australian New Zealand Clinical Trials Registry (ANZCTR). ANZCTR.org.au https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12624001123538 (2026)."},{"key":"983_CR211","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06229366 (2025)."},{"key":"983_CR212","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05983198 (2026)."},{"key":"983_CR213","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06881823 (2025)."},{"key":"983_CR214","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03490838 (2025)."},{"key":"983_CR215","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05720130 (2026)."},{"key":"983_CR216","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05613738 (2024)."},{"key":"983_CR217","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06237491 (2024)."},{"key":"983_CR218","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06250244 (2024)."},{"key":"983_CR219","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06809426 (2025)."},{"key":"983_CR220","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06377683 (2025)."},{"key":"983_CR221","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07363486 (2026)."},{"key":"983_CR222","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07117760 (2026)."},{"key":"983_CR223","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07381582 (2026)."},{"key":"983_CR224","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04868604 (2026)."},{"key":"983_CR225","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03822871 (2024)."},{"key":"983_CR226","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06217822 (2026)."},{"key":"983_CR227","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06052306 (2026)."},{"key":"983_CR228","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04876651 (2026)."},{"key":"983_CR229","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06520345 (2026)."},{"key":"983_CR230","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06549465 (2025)."},{"key":"983_CR231","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06492122 (2026)."},{"key":"983_CR232","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05160051 (2024)."},{"key":"983_CR233","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05262855 (2026)."},{"key":"983_CR234","doi-asserted-by":"publisher","first-page":"E523","DOI":"10.1097\/RLU.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi, M. et al. Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study. Clin. Nucl. Med. 46, E523\u2013E530 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"983_CR235","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler, W. P. et al. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin. Cancer Res. 28, 4346\u20134353 (2022).","journal-title":"Clin. Cancer Res."},{"key":"983_CR236","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04939610 (2026)."},{"key":"983_CR237","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07434180 (2026)."},{"key":"983_CR238","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06880757 (2025)."},{"key":"983_CR239","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05432193 (2025)."},{"key":"983_CR240","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05723640 (2025)."},{"key":"983_CR241","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06898437 (2025)."},{"key":"983_CR242","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05400967 (2024)."},{"key":"983_CR243","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06562192 (2026)."},{"key":"983_CR244","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07261631 (2026)."},{"key":"983_CR245","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06356922 (2026)."},{"key":"983_CR246","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06132737 (2026)."},{"key":"983_CR247","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05557708 (2025)."},{"key":"983_CR248","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05868174 (2024)."},{"key":"983_CR249","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07197580 (2026)."},{"key":"983_CR250","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05706129 (2025)."},{"key":"983_CR251","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05533242 (2026)."},{"key":"983_CR252","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1586\/14737140.2.5.485","volume":"2","author":"AJ Grillo-L\u00f3pez","year":"2002","unstructured":"Grillo-L\u00f3pez, A. J. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev. Anticancer Ther. 2, 485\u2013493 (2002).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"983_CR253","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02665065 (2023)."},{"key":"983_CR254","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07157514 (2025)."},{"key":"983_CR255","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03867682 (2023)."},{"key":"983_CR256","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03932318 (2023)."},{"key":"983_CR257","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02575963 (2023)."},{"key":"983_CR258","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05889728 (2023)."},{"key":"983_CR259","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02931929 (2019)."},{"key":"983_CR260","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03698370 (2024)."},{"key":"983_CR261","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03724253 (2020)."},{"key":"983_CR262","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03872778 (2026)."},{"key":"983_CR263","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06247995 (2026)."},{"key":"983_CR264","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05633160 (2025)."},{"key":"983_CR265","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05283330 (2026)."},{"key":"983_CR266","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06726161 (2026)."},{"key":"983_CR267","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07100730 (2026)."},{"key":"983_CR268","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05605522 (2025)."},{"key":"983_CR269","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06650605 (2026)."},{"key":"983_CR270","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06305962 (2026)."},{"key":"983_CR271","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05130255 (2026)."},{"key":"983_CR272","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05799274 (2026)."},{"key":"983_CR273","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05655312 (2026)."},{"key":"983_CR274","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05593107 (2024)."},{"key":"983_CR275","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06648317 (2024)."},{"key":"983_CR276","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04644770 (2026)."},{"key":"983_CR277","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03746431 (2026)."},{"key":"983_CR278","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01898273 (2015)."},{"key":"983_CR279","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01778088 (2014)."},{"key":"983_CR280","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02952508 (2016)."},{"key":"983_CR281","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03275402 (2024)."},{"key":"983_CR282","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04167618 (2023)."},{"key":"983_CR283","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04315246 (2022)."},{"key":"983_CR284","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01384253 (2016)."},{"key":"983_CR285","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04467515 (2025)."},{"key":"983_CR286","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04199741 (2026)."},{"key":"983_CR287","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06155994 (2023)."},{"key":"983_CR288","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03647657 (2022)."},{"key":"983_CR289","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02088645 (2026)."},{"key":"983_CR290","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06376253 (2026)."},{"key":"983_CR291","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01304797 (2017)."},{"key":"983_CR292","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02735798 (2017)."},{"key":"983_CR293","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03712423 (2020)."},{"key":"983_CR294","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04899908 (2026)."},{"key":"983_CR295","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03818386 (2024)."},{"key":"983_CR296","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02820454 (2019)."},{"key":"983_CR297","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04881032 (2025)."},{"key":"983_CR298","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03308604 (2021)."},{"key":"983_CR299","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04789486 (2026)."},{"key":"983_CR300","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04784221 (2025)."},{"key":"983_CR301","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01770353 (2019)."},{"key":"983_CR302","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01887717 (2021)."},{"key":"983_CR303","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT00109954 (2016)."},{"key":"983_CR304","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01135056 (2018)."},{"key":"983_CR305","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01895257 (2017)."},{"key":"983_CR306","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01721954 (2019)."},{"key":"983_CR307","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT00735241 (2015)."},{"key":"983_CR308","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02807181 (2025)."},{"key":"983_CR309","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02975739 (2018)."},{"key":"983_CR310","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05191498 (2024)."},{"key":"983_CR311","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05880472 (2025)."},{"key":"983_CR312","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01031784 (2012)."},{"key":"983_CR313","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01612325 (2015)."},{"key":"983_CR314","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04269499 (2021)."},{"key":"983_CR315","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05183776 (2023)."},{"key":"983_CR316","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06302400 (2025)."},{"key":"983_CR317","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03437382 (2021)."},{"key":"983_CR318","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05609448 (2023)."},{"key":"983_CR319","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05451862 (2025)."},{"key":"983_CR320","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01332669 (2015)."},{"key":"983_CR321","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03007225 (2020)."},{"key":"983_CR322","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04803019 (2021)."},{"key":"983_CR323","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02460991 (2021)."},{"key":"983_CR324","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07322848 (2026)."},{"key":"983_CR325","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04912258 (2021)."},{"key":"983_CR326","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05794971 (2023)."},{"key":"983_CR327","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06555003 (2025)."},{"key":"983_CR328","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06271421 (2024)."},{"key":"983_CR329","unstructured":"German Clinical Trials Register. DRKS.de https:\/\/drks.de\/search\/en\/trial\/DRKS00005476 (2017)."},{"key":"983_CR330","unstructured":"German Clinical Trials Register. DRKS.de https:\/\/drks.de\/search\/en\/trial\/DRKS00023339 (2026)."},{"key":"983_CR331","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05010759 (2023)."},{"key":"983_CR332","unstructured":"Nanobiotix receives European approval for Hensify therapy for sarcoma. The Cancer Letter https:\/\/cancerletter.com\/drugs-and-targets\/20190405_7d\/ (2019)."},{"key":"983_CR333","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04892173 (2026)."},{"key":"983_CR334","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04862455 (2026)."},{"key":"983_CR335","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01946867 (2022)."},{"key":"983_CR336","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04834349 (2023)."},{"key":"983_CR337","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04484909 (2026)."},{"key":"983_CR338","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07224152 (2026)."},{"key":"983_CR339","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04505267 (2026)."},{"key":"983_CR340","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05039632 (2026)."},{"key":"983_CR341","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03589339 (2025)."},{"key":"983_CR342","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04615013 (2026)."},{"key":"983_CR343","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02721056 (2021)."},{"key":"983_CR344","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02805894 (2021)."},{"key":"983_CR345","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02736578 (2019)."},{"key":"983_CR346","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03134846 (2021)."},{"key":"983_CR347","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02855086 (2020)."},{"key":"983_CR348","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05929456 (2023)."},{"key":"983_CR349","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04638036 (2024)."},{"key":"983_CR350","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06699212 (2025)."},{"key":"983_CR351","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04511078 (2025)."},{"key":"983_CR352","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03384238 (2026)."},{"key":"983_CR353","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03405142 (2022)."},{"key":"983_CR354","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03582124 (2026)."},{"key":"983_CR355","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03510208 (2026)."},{"key":"983_CR356","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03154411 (2021)."},{"key":"983_CR357","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07063693 (2026)."},{"key":"983_CR358","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07279116 (2026)."},{"key":"983_CR359","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02901925 (2024)."},{"key":"983_CR360","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03282461 (2023)."},{"key":"983_CR361","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT00485563 (2012)."},{"key":"983_CR362","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01778920 (2016)."},{"key":"983_CR363","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01994369 (2018)."},{"key":"983_CR364","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02000778 (2018)."},{"key":"983_CR365","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01778933 (2018)."},{"key":"983_CR366","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT00329368 (2012)."},{"key":"983_CR367","unstructured":"On Target Laboratories announces US FDA acceptance and priority review of new drug application for pafolacianine sodium injection for identification of ovarian cancer during surgery. PRNewswire https:\/\/www.prnewswire.com\/news-releases\/on-target-laboratories-announces-us-fda-acceptance-and-priority-review-of-new-drug-application-for-pafolacianine-sodium-injection-for-identification-of-ovarian-cancer-during-surgery-301239430.html (2021)."},{"key":"983_CR368","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06849544 (2026)."},{"key":"983_CR369","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05946603 (2025)."},{"key":"983_CR370","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04574401 (2021)."},{"key":"983_CR371","unstructured":"The UK\u2019s Clinical Study Registry. ISRCTN.com https:\/\/www.isrctn.com\/ISRCTN10046036 (2017)."},{"key":"983_CR372","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03113825 (2021)."},{"key":"983_CR373","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02391194 (2017)."},{"key":"983_CR374","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03659448 (2024)."},{"key":"983_CR375","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04642924 (2020)."},{"key":"983_CR376","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06280690 (2024)."},{"key":"983_CR377","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04737213 (2021)."},{"key":"983_CR378","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04755920 (2024)."},{"key":"983_CR379","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05965817 (2024)."},{"key":"983_CR380","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05984810 (2024)."},{"key":"983_CR381","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02973672 (2019)."},{"key":"983_CR382","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03686215 (2023)."},{"key":"983_CR383","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04440982 (2025)."},{"key":"983_CR384","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02584244 (2026)."},{"key":"983_CR385","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03441464 (2022)."},{"key":"983_CR386","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03834272 (2026)."},{"key":"983_CR387","unstructured":"Overview of medical research in the Netherlands. onderzoekmetmensen.nl https:\/\/onderzoekmetmensen.nl\/en\/trial\/48830 (2025)."},{"key":"983_CR388","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03161418 (2017)."},{"key":"983_CR389","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03579602 (2024)."},{"key":"983_CR390","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05316688 (2026)."},{"key":"983_CR391","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02464332 (2016)."},{"key":"983_CR392","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02097875 (2015)."},{"key":"983_CR393","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02234297 (2016)."},{"key":"983_CR394","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02496065 (2017)."},{"key":"983_CR395","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05752149 (2025)."},{"key":"983_CR396","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04191460 (2025)."},{"key":"983_CR397","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05518071 (2024)."},{"key":"983_CR398","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06713564 (2026)."},{"key":"983_CR399","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02807597 (2025)."},{"key":"983_CR400","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05900986 (2026)."},{"key":"983_CR401","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04105062 (2021)."},{"key":"983_CR402","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07276789 (2026)."},{"key":"983_CR403","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03333031 (2023)."},{"key":"983_CR404","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04950166 (2024)."},{"key":"983_CR405","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03735680 (2023)."},{"key":"983_CR406","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05048082 (2024)."},{"key":"983_CR407","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clgc.2021.03.011","volume":"19","author":"O Aras","year":"2021","unstructured":"Aras, O. et al. Small molecule, multimodal, [18F]-PET and fluorescence imaging agent targeting prostate-specific membrane antigen: first-in-human study. Clin. Genitourin. Cancer 19, 405\u2013416 (2021).","journal-title":"Clin. Genitourin. Cancer"},{"key":"983_CR408","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04167969 (2026)."},{"key":"983_CR409","unstructured":"German Clinical Trials Register. DRKS.de https:\/\/drks.de\/search\/en\/trial\/DRKS00020942 (2020)."},{"key":"983_CR410","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03699332 (2019)."},{"key":"983_CR411","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02497599 (2021)."},{"key":"983_CR412","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02910804 (2018)."},{"key":"983_CR413","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03407781 (2024)."},{"key":"983_CR414","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03749850 (2021)."},{"key":"983_CR415","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01640847 (2017)."},{"key":"983_CR416","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02536183 (2023)."},{"key":"983_CR417","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04240639 (2023)."},{"key":"983_CR418","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02680535 (2021)."},{"key":"983_CR419","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05937620 (2026)."},{"key":"983_CR420","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05555199 (2025)."},{"key":"983_CR421","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02106598 (2026)."},{"key":"983_CR422","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1308\/rcsann.2021.0084","volume":"103","author":"N Wei","year":"2021","unstructured":"Wei, N. et al. Sentinel lymph node biopsy with carbon nanoparticle suspension after neoadjuvant chemotherapy for breast cancer patients. Ann. R. Coll. Surg. Engl. 103, 752\u2013756 (2021).","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"983_CR423","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36307","volume":"10","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. The clinical value of carbon nanoparticles in sentinel lymph node biopsy for early vulvar cancer. Heliyon 10, e36307 (2024).","journal-title":"Heliyon"},{"key":"983_CR424","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.surg.2016.04.017","volume":"160","author":"W Yu","year":"2016","unstructured":"Yu, W. et al. Potential role for carbon nanoparticles to guide central neck dissection in patients with papillary thyroid cancer. Surgery 160, 755\u2013761 (2016).","journal-title":"Surgery"},{"key":"983_CR425","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/1471-0528.16504","volume":"128","author":"X Ya","year":"2021","unstructured":"Ya, X. et al. Role of carbon nanoparticle suspension in sentinel lymph node biopsy for early-stage cervical cancer: a prospective study. BJOG 128, 890\u2013898 (2021).","journal-title":"BJOG"},{"key":"983_CR426","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/jog.13635","volume":"44","author":"SX Yang","year":"2018","unstructured":"Yang, S. X. et al. Analysis of 246 sentinel lymph node biopsies of patients with clinical primary breast cancer by application of carbon nanoparticle suspension. J. Obstet. Gynaecol. Res. 44, 1150\u20131157 (2018).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"983_CR427","first-page":"447","volume":"16","author":"W Yu","year":"2018","unstructured":"Yu, W., Xu, G., Sun, J. & Zhong, N. Carbon nanoparticles guide contralateral central neck dissection in patients with papillary thyroid cancer. Oncol. Lett. 16, 447\u2013452 (2018).","journal-title":"Oncol. Lett."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00983-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:03:19Z","timestamp":1792713799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00983-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":427,"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1038\/s41568-026-00983-3","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"28 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.D. is founder and shareholder of Aurelius Therapeutics BV. M.S.B. is co-inventor on patent applications related to the C\u2032 dot technology. X.C. is co-founder of and holds shares in Yantai Lannacheng Biotechnology Co., Ltd.\u00a0G.M.v.D. is founder, shareholder, and CEO of TRACER Europe BV, and advisory board member of QT Sense BV.\u00a0W.A.W. reports grants to the institution from Blue Earth Diagnostics, Blue Earth Therapeutics, ITM, Novartis and\u00a0Siemens, and other support to the institution from Actinium Pharmaceuticals, Blue Earth Diagnostics, Blue Earth Therapeutics, Evergreen, ITM, Lilly, Nuclidium, Pentixapharm, Perspective, Razye Bio\u00a0and Ratio Therapeutics;\u00a0he has acted as a consultant\/served on advisory boards for Blue Earth Diagnostics, Curium, ITM, Novartis and\u00a0Ratio Therapeutics.\u00a0F.K. and T.L. are\u00a0co-founders of SonoMAC GmbH, and\u00a0co-inventors on patent\u00a0applications related to theranostic microbubbles and polymeric micelles. F.K. is a consultant of Fujifilm Visualsonics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}